Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome

Overview

This study is being done to evaluate whether the medication, febuxostat, can improve the degree of insulin resistance and other features of the metabolic syndrome (high blood pressure, elevated insulin levels, excess body fat around the waist, and/or high cholesterol) by lowering uric acid levels in the blood.

Full Title of Study: “Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2015

Detailed Description

The metabolic syndrome (MS) is characterized by a constellation of metabolic features including dyslipidemia, hyperglycemia, hypertension, obesity, and insulin resistance. This cluster of features is strongly associated with type 2 diabetes, atherosclerotic cardiovascular disease, and increased cardiovascular and all-cause mortality. Hyperuricemia (elevated serum uric acid) is associated with insulin resistance and features of the MS in cross-sectional epidemiological studies. However, it remains unclear whether this association is causal or simply coincidental. If hyperuricemia CAUSES insulin resistance, then lowering serum uric acid by pharmacological means may result in improved insulin sensitivity and reversal of features of the metabolic syndrome. In some recent small studies, lowering serum uric acid with allopurinol was associated with improvement in some of the features and/or complications of the MS: Allopurinol use resulted in reduction in blood pressure in adolescents and improvement in exercise capacity in patients with chronic stable angina. A low urine pH is strongly associated with insulin resistance, and individual features of the metabolic syndrome. Similarly, a low fractional excretion of uric acid is also associated with metabolic syndrome feature. We therefore would like to examine the effect on febuxostat on these two parameters which have been linked with the metabolic syndrome. The goal of this study is to evaluate whether pharmacological lowering of serum uric acid with the medication febuxostat is associated with improvement in the degree of insulin resistance and various features of the metabolic syndrome.

Interventions

  • Drug: Febuxostat
    • One 40 mg tablet once a day for 6 months

Arms, Groups and Cohorts

  • Experimental: Febuxostat
    • Adult patients (age > 21 years) with gout and hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women) requiring uric acid lowering therapy.

Clinical Trial Outcome Measures

Primary Measures

  • BMI
    • Time Frame: 6 months
  • Serum Uric Acid
    • Time Frame: 6 months
  • Serum Creatinine
    • Time Frame: 6 months
  • Ambulatory Systolic Blood Pressure
    • Time Frame: 6 months
    • Systolic BP by ambulatory blood pressure monitor.
  • Ambulatory Diastolic Blood Pressure
    • Time Frame: 6 months
    • Diastolic BP by ambulatory blood pressure monitor.
  • Serum Glucose
    • Time Frame: 6 months
  • Serum Insulin
    • Time Frame: 6 months
  • Insulin Sensitivity Measured by HOMA (HOmeostasis Model Assessment)
    • Time Frame: 6 months
  • Seum Total Cholesterol
    • Time Frame: 6 months
  • Serum HDL-cholesterol
    • Time Frame: 6 months
  • Serum Triglycerides
    • Time Frame: 6 months
  • Urine Uric Acid
    • Time Frame: 6 months
  • Urine Creatinine
    • Time Frame: 6 months
  • Fractional Excretion UA
    • Time Frame: 6 months
  • Urine pH
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • Age > 21 years – Gout – Hyperuricemia (serum uric acid > 7.0 mg/dl in men and >6.0 mg/dl in women). Exclusion Criteria:

  • Current treatment with insulin, azathioprine, mercaptopurine, or theophylline. – Treatment with febuxostat, allopurinol or other uricosuric agents (including losartan, probenecid) within the past year – Uncontrolled hypertension (clinic systolic blood pressure > 160 mmHg or diastolic blood pressure > 90 mmHg within the past 6 months) – Uncontrolled diabetes mellitus (HbA1c > 7%) – estimated GFR < 60 ml/min by MDRD – Elevated liver function tests (AST or ALT greater than 3 times the upper limit of normal) – Pregnancy

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Texas Southwestern Medical Center
  • Provider of Information About this Clinical Study
    • Principal Investigator: Naim Maalouf, Assistant Professor of Medicine – University of Texas Southwestern Medical Center
  • Overall Official(s)
    • Naim M Maalouf, MD, Principal Investigator, UT Southwestern Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.